FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)-- Gilead Sciences, Inc. and Kymera Therapeutics, Inc. (), today announced that they have entered into an exclusive option and license ...

Kymera will lead all research activities for the CDK2 program, while Foster City, Calif., biopharmaceutical company Gilead will have global rights to develop, manufacture and commercialize all ...

Gilead Sciences partners with Kymera Therapeutics in a $750 million deal to develop molecular glue degraders for breast cancer treatment.

Gilead Sciences Inc. (NASDAQ: ... Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock ...

Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences Inc. will collaborate on a molecular ...

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...

Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration Provided by Dow Jones Jun 25, 2025, 11:46:00 AM. By Colin Kellaher . Gilead Sciences and Kymera Therapeutics have inked an ...